SUZHOU and SHANGHAI China, May 21, 2023 -Forlong Biotechnology, a clinical stage biotech dedicated to developing next-generation cytokine therapeutics, today announced that it received the Phase I Clinical Trial of FL115(i.v.) as monotherapy in advanced solid tumors.

FL115 is a next-generation, long-acting IL-15/IL-15Rα monomeric Fc-fusion protein wholly discovered and patented by Forlong Biotech. Its unique single-arm structure delivers antibody-like yields, enhanced tumor penetration, and an exemplary safety profile. Pre-clinical studies demonstrate FL115 has significantly wider therapeutic index than comparator IL-15 agents, enabling efficacious dosing at markedly higher exposure levels. These attributes position FL115 as a potential best-in-class backbone of future immuno-oncology regimens.

About Forlong Biotechnology

Forlong Biotechnology is a clinical stage biotechnology company dedicated to developing next-generation cytokine therapeutics. Based on synthetic immunology, the company has established four core technology platforms, committed to overcoming the challenges of developing cytokine drugs.